XORTX Therapeutics (XORTX Therapeutics) Days Payable

: 0.00 (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

XORTX Therapeutics's average Accounts Payable for the three months ended in Sep. 2023 was $0.32 Mil. XORTX Therapeutics's Cost of Goods Sold for the three months ended in Sep. 2023 was $0.00 Mil.

The historical rank and industry rank for XORTX Therapeutics's Days Payable or its related term are showing as below:

XRTX's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 144.69
* Ranked among companies with meaningful Days Payable only.

XORTX Therapeutics's Days Payable stayed the same from Sep. 2022 (0.00) to Sep. 2023 (0.00). stayed the same

XORTX Therapeutics Days Payable Historical Data

The historical data trend for XORTX Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Payable

XORTX Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Days Payable																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, XORTX Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics Days Payable Distribution

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Days Payable falls into.

XORTX Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

XORTX Therapeutics's Days Payable for the fiscal year that ended in Dec. 2022 is calculated as

	Days Payable (A: Dec. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2021 )	+	Accounts Payable (A: Dec. 2022 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2022 )	*	Days in Period
=	( (0.322	+	1.296)	/	2 )	/	0	*	365
=	0.809					/	0	*	365
=	N/A

XORTX Therapeutics's Days Payable for the quarter that ended in Sep. 2023 is calculated as:

	Days Payable (Q: Sep. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Sep. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2023 )	*	Days in Period
=	( (0.238	+	0.394)	/	2 )	/	0	*	365 / 4
=	0.316					/	0	*	365 / 4
=	N/A

XORTX Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (XORTX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

ANUA:Germany XRTX:Canada

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.